# A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Source: https://onco.cc/trials/nct07005154/  
OnCo record `nct07005154` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Prednisone, Abiraterone acetate in prostate cancer, run by Astellas Pharma Global Development, Inc., now recruiting.

## Summary

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer is a phase 2 interventional study registered as NCT07005154 by Astellas Pharma Global Development, Inc., with 218 participants planned, started 2025-08-19 and due to reach its primary completion in 2032-05-31. Interventions recorded: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone. Conditions listed: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07005154
- Phase: 2
- Setting: A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 218

## Sources

- ClinicalTrials.gov NCT07005154: https://clinicaltrials.gov/study/NCT07005154

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct07005154.json